Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013:2013:138484.
doi: 10.1155/2013/138484. Epub 2013 Jun 4.

A systematic review and meta-analysis of buyang huanwu decoction in animal model of focal cerebral ischemia

Rui-Li Wei  1 , Hai-Juan Teng, Bo Yin, Yang Xu, Yue Du, Fang-Pin He, Ke-Tan Chu, Ben-Yan Luo, Guo-Qing Zheng
Affiliations

A systematic review and meta-analysis of buyang huanwu decoction in animal model of focal cerebral ischemia

Rui-Li Wei et al. Evid Based Complement Alternat Med. 2013.

Abstract

Buyang Huanwu Decoction (BHD) is a well-known Chinese herbal prescription for ischemic stroke. The objective of this systematic review and meta-analysis is to provide the current evidence for neuroprotective effects of BHD and its possible mechanisms in animal models of focal ischemia. A systematic literature search, through October 2012, was performed using six databases. The outcome measures assessed were infarct size and/or neurological score. Fifty-six studies with 1270 animals that met the inclusion criteria were identified. The median score for methodological quality was 3 with a range of 2 to 6. Compared with vehicle or no treatment controls, BHD gave a 37% improvement in outcome for all doses ranging from 1.0 g/kg to 60 g/kg at each time point that BHD was administered (P < 0.01). Efficacy was higher in mouse models that utilized suture occlusion and temporary ischemia. The neuroprotective effects of BHD are involved in multiple mechanisms and act upon multiple cell types. In conclusion, BHD possesses substantial neuroprotective effects in experimental stroke probably as a result of the multitarget therapy strategy typically utilized in traditional Chinese medicine. Future research should examine the presence of possible experimental bias and an in-depth study of herbal compound preparations.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Flowchart of study selection process.
Figure 2
Figure 2
Point estimates and 95% CIs of effect size by (a) reported study quality score, (b) timing of treatment, (c) BHD dose and (d) time to outcome measurement. The 95% CI for the global estimate is shown as a grey band.
Figure 3
Figure 3
Funnel plot of the effect size of BHD treatment for animal models of focal ischemia.
Figure 4
Figure 4
Point estimates of effect size and 95% CIs by (a) duration of occlusion, (b) method of ischemia induction, (c) route of drug delivery, (d) animal species, (e) measurement method of outcome, and (f) data published or unpublished. The 95% CI for the global estimate is shown as a grey band.
See this image and copyright information in PMC

References

    1. O’Collins VE, Macleod MR, Donnan GA, Horky LL, Van Der Worp BH, Howells DW. 1,026 Experimental treatments in acute stroke. Annals of Neurology. 2006;59(3):467–477. - PubMed
    1. Savitz SI, Fisher M. Future of neuroprotection for acute stroke: in the aftermath of the SAINT trials. Annals of Neurology. 2007;61(5):396–402. - PubMed
    1. Wang QR. Yilin Gaicuo. Beijing, China: People’s Medical Publishing House; 2005.
    1. Johnston L. Buyang Huanwu Decoction. http://www.healingtherapies.info/Buyang.htm.
    1. Wang HW, Liou KT, Wang YH, et al. Deciphering the neuroprotective mechanisms of Bu-yang Huan-wu Decoction by an integrative neurofunctional and genomic approach in ischemic stroke mice. Journal of Ethnopharmacology. 2011;138(1):22–33. - PubMed

LinkOut - more resources